Palbociclib
- Generic Name
- Palbociclib
- Brand Names
- Ibrance
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N7O2
- CAS Number
- 571190-30-2
- Unique Ingredient Identifier
- G9ZF61LE7G
- Background
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.
...
- Indication
Palbociclib is indicated in combination with letrozole as initial endocrine-based therapy for the treatment of human epidermal growth factor receptor type 2 (HER2)-negative and hormone receptor(HR)-positive tumors in adult patients with advanced/metastatic breast cancer. It is as well approved in combination with fulvestrant in patients with disease progress...
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer
- Associated Therapies
- -
Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- Emory University
- Registration Number
- NCT04585724
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT04567420
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
- First Posted Date
- 2020-09-11
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 992
- Registration Number
- NCT04546009
- Locations
- 🇺🇸
Long Beach Memorial Medical Center, Fountain Valley, California, United States
🇺🇸Orange Coast Memorial Medical Center, Fountain Valley, California, United States
🇺🇸Kaiser Permanente - San Leandro Medical Center, San Leandro, California, United States
Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China
- Conditions
- Interventions
- First Posted Date
- 2020-08-25
- Last Posted Date
- 2020-08-25
- Target Recruit Count
- 612
- Registration Number
- NCT04526028
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy
- Conditions
- Interventions
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2020-08-24
- Lead Sponsor
- Istituti Clinici Scientifici Maugeri SpA
- Target Recruit Count
- 191
- Registration Number
- NCT04524728
- Locations
- 🇮🇹
Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Hormone Receptor Positive Breast CarcinomaLocally Advanced Breast CarcinomaMetastatic Breast CarcinomaMetastatic Endometrioid AdenocarcinomaMetastatic Primary Peritoneal Carcinoma
- Interventions
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- Pamela Munster
- Registration Number
- NCT04498520
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1068
- Registration Number
- NCT04478266
- Locations
- 🇺🇸
Investigational Site Number :8400029, Santa Monica, California, United States
🇺🇸Investigational Site Number :8400038, Fullerton, California, United States
🇺🇸Investigational Site Number :8400013, Westwood, Kansas, United States
Palbociclib and INCMGA00012 in People With Advanced Liposarcoma
- Conditions
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT04438824
- Locations
- 🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
- Conditions
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT04439201
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)
- Conditions
- Interventions
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2023-02-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 221
- Registration Number
- NCT04436744
- Locations
- 🇺🇸
UCLA - Burbank, Burbank, California, United States
🇺🇸UCLA Hematology/Oncology-San Luis Obispo, San Luis Obispo, California, United States
🇺🇸Orlando Health Inc., Orlando, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.